Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

Reaffirms Outlook for Continued Growth

CAMBRIDGE, Mass., Feb. 13 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported financial results for the full year and fourth quarter of 2007 and provided an outlook for continued strong growth in 2008 and beyond.

Full-Year 2007

-- Total revenue in 2007 increased 20 percent to $3.8 billion from $3.2

billion in 2006. The increase was broadly driven by growth across all

segments of the company.

-- GAAP net income was $480.2 million, or $1.74 per diluted share,

compared with a net loss of $16.8 million, or $0.06 per diluted share,

for the previous year.

-- Non-GAAP net income increased 27 percent to $939.9 million, compared

with $742.7 million in 2006.

-- Non-GAAP earnings increased 25 percent to $3.47 per diluted share from

$2.77, exceeding the increased guidance of $3.35-$3.40 that Genzyme

provided in July.

-- The company generated approximately $1 billion in cash from operations

and increased its ending cash position to $1.5 billion while completing

two acquisitions, expanding its manufacturing infrastructure, and

repurchasing approximately 3.5 million shares under a three-year

program to reduce the dilutive effect of equity compensation.

-- Genzyme also continued to make excellent progress in building its

business to drive future growth. The company:

-- Expanded its emerging oncology franchise by securing worldwide

rights to its leukemia drug Clolar(R) (clofarabine) through the

acquisition of Bioenvision Inc.

-- Obtained marketing approval for four
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Air Conditioning & Heating ... an authorized Daikin comfort pro dealer. This means that ... heating and cooling system equipment. Only a select few ... reviewed before being approved. , Daikin co-developed an R-410A ... Split System Air Conditioning Market. They are also the ...
(Date:7/22/2014)... 2014 United Benefit Advisors (UBA), the ... Les McPhearson, an insurance veteran with more than 15 ... and be based in the company's Chicago office. , ... that Les chose to accept this important, strategic position ... the many challenges facing UBA and its Partners as ...
(Date:7/22/2014)... By Steven Reinberg ... -- Women who are obese during pregnancy may be more ... new review suggests. "We found that, compared with children ... overweight or obese during pregnancy had up to 20 to ... Erick Forno, an assistant professor of pediatrics at Children,s Hospital ...
(Date:7/22/2014)... the Clean Plate Club you eat pretty much everything ... A new Cornell University study shows that the average adult ... or her plate. "If you put it on ... Ph.D., author of the forthcoming book, Slim by Design, Professor ... Lab. , Wansink and co-author Katherine Abowd Johnson analyzed 1179 ...
(Date:7/22/2014)... July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014”) championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). , ...
Breaking Medicine News(10 mins):Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... pretext for multinational corporations to take control of the precious ... With sales of over $35 billion worldwide in the ... buy up pristine springs in some of the country's most ... one-third of the U.S. market and sells 70 different brand ...
... overdose during pregnancy could be harmful, according to an Iranian ... combat anemia in pregnancy but many women take extra iron. ... carry enough oxygen due to low number of red blood ... carry normal amounts of oxygen. Common symptoms of anemia include ...
... for Inclusive Communities (CAIC) has recently joined the fight ... the majority of state and national disability rights organizations ... group that works on behalf of groups with developmental ... as a new national AP/Ipsis poll was released indicating ...
... the Pharmaceutical Research and Manufacturers of America (PhRMA) finds ... of the three leading causes of death of Americans ... currently in clinical trials or under review by the ... and stroke are still leading causes of death in ...
... advent of a possible new blockbuster drug and greater ... drug addictions, global sales of smoking cessation and ... little over $1.1 billion in 2005 to more than ... Addiction Treatments: A World Market Analysis, a new study ...
... on cardiometabolic risk factors beyond those expected from weight ... not be due to the drug itself, reports an ... Bulletin (DTB). ,Advertisements for rimonabant (sold ... an estimated 50% of the effects on cardiometabolic ...
Cached Medicine News:Health News:Multinationals Exploit Groundwater Sources, and People Suffer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 3Health News:Multinationals Exploit Groundwater Sources, and People Suffer 4Health News:Multinationals Exploit Groundwater Sources, and People Suffer 5Health News:More Than 270 Medicines in Testing for Heart Disease and Stroke 2Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2
(Date:7/22/2014)... -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN ... first lots of Fluzone ® (Influenza Vaccine) for the ... U.S. Food and Drug Administration (FDA) for distribution. The lots ... at least 65 million doses of seasonal influenza vaccine manufactured ... care providers and pharmacies in August. The ...
(Date:7/22/2014)... 2014  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... dosing of patients in its ongoing Phase 2 trial ... under the revised clinical protocol agreed to with the ... of Halozyme,s proprietary recombinant human hyaluronidase under development for ... "Our diligent effort to rapidly re-initiate patient ...
(Date:7/22/2014)... PHILADELPHIA ,  July 22, 2014 /PRNewswire/ ... business of Thomson Reuters , the world,s ... and professionals, today announced Cortellis Clinical ... database, marked an industry-first milestone with the ... thus providing pharmaceutical professionals with greater and ...
Breaking Medicine Technology:Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3
... Inc. the leading provider of computerized maintenance management ... to announce the latest release of TMS 2012.5.5.  ... have included a number of new features and ... The new release of TMS will continue ...
... NEW YORK, Feb. 29, 2012  TheraBiogen, Inc. (OTC BB: ... for aiding in the relief of allergies, cold and ... its Thera Max® Cold and Flu brand is receiving ... The Company is taking its new homeopathic product, Thera ...
Cached Medicine Technology:Four Rivers Software Systems Launches TMS 2012.5.5 2Thera Max® Cold and Flu Brand Receives Great Benefits from Its Ongoing Social Media Marketing Awareness Program 2Thera Max® Cold and Flu Brand Receives Great Benefits from Its Ongoing Social Media Marketing Awareness Program 3
... matrix constructed of cross-linked collagen fibers ... through a proprietary 360 accretion process. ... aspirate, Healos provides an excellent environment ... differentiation. The hydroxyapatite-coated collagen microfibers in ...
Sharp Weitlaner Retractor....
Weitlaner retractor, blunt....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
Medicine Products: